UBS Group Cuts TransMedics Group (NASDAQ:TMDX) Price Target to $77.00

TransMedics Group (NASDAQ:TMDX) had its price objective decreased by UBS Group from $80.00 to $77.00 in a research note released on Wednesday morning,Benzinga reports. UBS Group currently has a neutral rating on the stock.

Other analysts have also recently issued reports about the stock. Canaccord Genuity Group reissued a “buy” rating and set a $124.00 target price on shares of TransMedics Group in a report on Tuesday, June 30th. Piper Sandler reissued an “overweight” rating and issued a $100.00 price target (down from $120.00) on shares of TransMedics Group in a research note on Wednesday. Zacks Research lowered shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Oppenheimer cut shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen cut TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $124.18.

TransMedics Group Price Performance

TMDX stock opened at $83.89 on Wednesday. The company has a quick ratio of 6.19, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. The stock’s 50 day moving average is $73.72 and its two-hundred day moving average is $98.69. The company has a market capitalization of $2.90 billion, a PE ratio of 21.57 and a beta of 1.90. TransMedics Group has a 52-week low of $60.10 and a 52-week high of $156.00.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). The company had revenue of $189.95 million for the quarter, compared to the consensus estimate of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The company’s revenue was up 20.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.92 earnings per share. Analysts predict that TransMedics Group will post 1.61 earnings per share for the current fiscal year.

Insider Activity at TransMedics Group

In related news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the sale, the director owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

A number of large investors have recently bought and sold shares of TMDX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of TransMedics Group by 11.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock worth $119,997,000 after acquiring an additional 113,817 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in TransMedics Group by 50.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after purchasing an additional 322,353 shares during the last quarter. Geode Capital Management LLC raised its position in shares of TransMedics Group by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 816,474 shares of the company’s stock valued at $99,339,000 after buying an additional 2,903 shares during the last quarter. Two Sigma Investments LP raised its holdings in TransMedics Group by 54.2% in the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock valued at $71,291,000 after acquiring an additional 223,409 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in TransMedics Group by 43.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company’s stock worth $69,338,000 after purchasing an additional 171,810 shares during the period. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.